Form 4: Bausch Health Companies Inc. Executive John S. Barresi Reports Changes in Beneficial Ownership

John S. Barresi, SVP, Controller & CAO of Bausch Health Companies Inc., reports acquisition and disposal of common shares and restricted share units.

Summary

• On February 29, 2024, John S. Barresi acquired 39,126 common shares of Bausch Health Companies Inc. through the award of restricted share units (RSUs) at a price of $0.
• These RSUs will vest in two equal installments on the first two anniversaries of the grant date, contingent upon continued service.
• Vested RSUs are settled in common shares.
• On March 1, 2024, Barresi disposed of 3,188 common shares at a price of $9.89.
• This disposal was to satisfy tax withholding obligations upon the vesting of Restricted Share Units.
• Following these transactions, Barresi beneficially owns 107,064 common shares.

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing primarily reflects routine transactions related to RSU vesting and tax obligations. The acquisition of RSUs is a positive sign, but the disposal of shares for tax purposes is a neutral event.

Positives

• The acquisition of 39,126 common shares through RSUs indicates confidence in the company's future performance.

Negatives

• The disposal of 3,188 shares, while for tax obligations, slightly reduces Barresi's direct holdings.

Risks

• The vesting of RSUs is contingent upon continued service, creating a potential risk if Barresi were to leave the company before full vesting.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs implies a continued commitment from the reporting person to the company's future.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be an indicator of management's sentiment towards the company's prospects.

Comparison to Industry Standards

• Monitoring insider transactions is a common practice in financial analysis to gauge executive sentiment.
• Comparing the volume and frequency of insider buying and selling activity at Bausch Health to peers like Teva Pharmaceuticals or Mylan (now Viatris) can provide a broader context.
• For example, consistent insider buying might signal strong confidence, while frequent selling could raise concerns.

Stakeholder Impact

• Shareholders may view the RSU acquisition as a positive signal of management's commitment.
• The disposal of shares for tax obligations is unlikely to have a significant impact on stakeholders.

Key Dates